Antibody-Drug Conjugates 2

• 6920 · PDF 靶向白血病性单核细胞与肿瘤相关巨噬细胞的同类首创CD64-ADC的临床前开发 Preclinical development of a first-in-class CD64-ADC to target leukemic monocytes and tumor-associated macrophages Lia Buffa, Cintia Garro, Constanza Marin, Alejandra Garcia, Diego Andino, Melisa Capitanelli, Laura Bertoldi, Florencia Villafanez, Natalia Monjes, Agustina Garcia-Melani, Laura Guantay, Daniela Arroyo, Alejandro Moyano, Gimena Ferreira, Belkys Marelli, Tarek Zaki, Gerardo Gatti, Candelaria Llorens de los Rios, Gaston Soria
• 6921 · PDF 膦酸酯-抗体药物偶联物：一类新型免疫刺激性ADC，驱动Vgamma9Vdelta2 T细胞的由内而外激活，从而实现选择性肿瘤细胞杀伤 Phosphonate-antibody-drug conjugates, a novel immunostimulatory class of ADCs driving inside-out activation of Vgamma9Vdelta2 T cells leading to selective tumor cell killing Mary J. van Helden, Genny Filliciotto, Wendela A. Kappers, Diels van den Dobbelsteen, Panagiota I. Spantidea, Marga Gunnewijk, Myrthe Rouwette, Anja Scholzen, Seline A. Zwarthoff, Stefanie J. J. Bartels, Sebastiaan Birkedal, Sanne H. C. van den Ouweland, Ellen W. H. Santegoeds-Lenssen, Robbin Tebes, Menno Winkel, Marc C. B. Parade, Lilian Driessen-Engels, Karin de Laat-Arts, Ivan Faraho, Inge M. J. Reinieren-Beeren, Giel Verhagen, Dorian van Kuijk, Daphne W. J. van Kuppeveld, Benny de Wit, Gijs Verheijden, Ruud Ubink, Benno Ingelse, Miranda M. C. Van der Lee, Wim H. A. Dokter
• 6922 · PDF BHB810：一种新型定点偶联的靶向CDH17的VHH-Fc ADC用于胃癌治疗 BHB810: A novel site-specific CDH17-directed VHH-Fc ADC for gastric cancer Ryan Henrici, Timothy Park, Melanie Montgomery, Barbara Steurer, Danielle Barreras, Natalie Alba, Srujan Vadlamudi, Hunter Elliott, Jon Wojciak, John Corbin, Peyton Greenside
• 6923 · PDF 以同类首创抗体药物偶联物靶向MUC1和MUC4的肿瘤特异性Tn糖型：GO-M100B和GO-M400的临床前疗效与转化潜力 Targeting tumor-specific Tn-glycoforms of MUC1 and MUC4 with first-in-class antibody-drug conjugates: Preclinical efficacy and translational potential of GO-M100B and GO-M400 Nisha Shrestha, Aaron Christopher Groen, Boris Klebanov, Constantine Theodoropulos, Hans H. Wandall
• 6925 · PDF 利用AI增强的多组学发现用于ADC开发的新型肿瘤选择性靶点 Leveraging AI-enhanced multi-omics discovery of novel tumor-selective targets for ADC development Daniel Montoro, Christoph Muus, Karthik Jagadeesh, Cecile Rouleau, Yueyue Shi, Sho Takahashi, James Meador, Ritika Singh
• 6926 · PDF 一种AI引导的双互补位DLL3靶向ADC展现出增强的临床前疗效 An AI-guided biparatopic DLL3-targeting ADC demonstrates enhanced preclinical efficacy Chuan Chen, Yue Wu, Chenpeng Su, Zhaohui Chen, Dandan Liu, Jiyuan Tian, Xiaoqian Chen, Yang He, Yongxin Shang, Rongmei Yan, Liang Tian, Jian Peng, Zhenping Zhu
• 6927 · PDF ADCE-T02——一种靶向组织因子的临床阶段抗体药物偶联物在头颈部鳞状细胞癌临床前模型中展现出强效疗效 ADCE-T02 - A clinical stage antibody drug conjugate targeting tissue factor demonstrates strong efficacy in preclinical models of head and neck squamous cell carcinoma Thomas Tuxen Poulsen, Olga Ilina, Pernille Barkholt, Daniela Pontieri, Jette Bomholt Lange, Jonathan Henry Wardman, Christophe Côme, Christina Hjæresen, Shu-Hui Liu, Xun Meng, Yue Zhang, Dominik Mumberg
• 6928 · PDF 靶向TROP2的双载荷抗体药物偶联物：靶向正交细胞杀伤机制的Multi-Payload Conjugates™ Dual-payload antibody drug conjugate targeting TROP2: Multi-Payload Conjugates™ targeting orthogonal mechanisms of cell killing Marco Lobba, Samantha Brady, Devin Trinter, Maxwell Nguyen, Chanez Symister, Andrew Lau, Derek Garcia-Almedina, Charlotte Choi, Saurabh Johri, Matthew Francis, Richard Kendall
• 6929 · PDF 利用新型TCR模拟抗体偶联药物(TCRm-ADC)靶向细胞内KRAS G12D/HLA-A11 pMHC，在临床前模型中展现出强效抗肿瘤活性 Targeting intracellular KRAS G12D /HLA-A11 pMHC with a novel TCR-mimic antibody-drug conjugate (TCRm-ADC) demonstrates potent antitumor activity in preclinical models Chia-Chun Chao, Wei-Ze Hong, Hsin-Yu Chang, Jhen-Yu Chen, Yi-Wen Jiang, K.S. Clifford Chao, Kevin Chih-Yang Huang
• 6930 · PDF BCG018——一种靶向ITGB6并搭载拓扑异构酶I抑制剂载荷的ADC，在PDX模型中被证实具有临床前疗效 Preclinical efficacy of BCG018, an ADC targeting ITGB6 and incorporating a topoisomerase I inhibitor payload, was demonstrated to be effective in PDX models Yi Yang, Mengran Li, Chengzhang Shang
• 6931 · PDF BCG044——一种靶向EpCAM和HER3、用于治疗结直肠癌及其他肿瘤的新型双特异性ADC的临床前研究 Preclinical study of BCG044, a novel bispecific ADC targeting EpCAM and HER3 for the treatment of colorectal and other tumors Jeremy Lee, Zhuolin Li, Chengzhang Shang, Yi Yang
• 6932 · PDF BCG045：一种同类首创的靶向TROP2和MUC1的双特异性ADC，在临床前研究中展现出有前景的肿瘤疗效和潜在降低的毒性 BCG045: A first-in-class bispecific ADC targeting TROP2 and MUC1 demonstrates promising tumor efficacy and potentially reduced toxicity in preclinical studies Jeremy Lee, Yifu Zhang, Chengzhang Shang, Yi Yang
• 6933 · PDF GQ1035：通过高通量筛选发现的、针对胃癌和卵巢癌新型靶点的同类首创ADC GQ1035: First-in-class ADC against novel targets for gastric cancer and ovarian cancer discovered via high-throughput screening​ Shanshan Xie, Meijun Xiong, Lina Wang, Yajun Sun, Chong Liu, Zhongsheng Hu, Xinju Gao, Yanwen Feng, Yu Han, Zengyan Mu, Paul H. Song, Gang Qin
• 6934 · PDF 利用精简的互补平台对ADC的载荷介导、Fc介导及靶点介导机制进行整合评估 Integrated evaluation of payload-, Fc-, and target-mediated mechanisms of ADCs using streamlined complementary platforms Alpana Prasad, Surekha Bonasu, Radhika Venkatnarayanan, Jennifer Lin-Jones, Jane E. Lamerdin, Gaurav Agrawal, Nguyen Ly, Jesus A. Diaz de Leon, Venkatesh Chari
• 6935 · PDF BCG029：一种靶向ADAM9、搭载新型拓扑异构酶I抑制剂载荷的ADC，在PDX模型中展现出强效疗效 BCG029: An ADAM9-Targeting ADC Featuring a Novel Topoisomerase I Inhibitor Payload Demonstrated Potent Efficacy in PDX Models Yong Xie, Mengran Li, Chengzhang Shang, Yi Yang
• 6936 · PDF 一种新型MSLN×CDH3双特异性抗体偶联药物(BsADC)展现出有前景的抗肿瘤疗效 A novel MSLN×CDH3 bispecific antibody-drug conjugate (BsADC) demonstrates promising anti-tumor efficacy Haochen Wei, Zihao Wang, Weiqiu Lan, Xi Yang, Kunying Hao, Jinhua Zhao, Yang Chen, Baihong Liu, Chengzhang Shang, Yi Yang
• 6937 · PDF BCG046：一种靶向CTF的CDCP1 ADC，展现出强效的体外和体内疗效 BCG046, a CDCP1 ADC that targets CTF, has demonstrated potent in vitro and in vivo efficacy Haochen Wei, Na Zhang, Chengzhang Shang, Yi Yang
• 6938 · PDF BCG026：FAP × GPC1双特异性ADC——一种针对胰腺癌及其他实体瘤中基质细胞和肿瘤细胞的新型靶向策略 BCG026: FAP × GPC1 bispecific ADC - A novel targeting approach for stromal and tumor cells in pancreatic cancer and other solid tumors Haochen Wei, Na Zhang, Kunying Hao, Chengzhang Shang, Yi Yang
• 6939 · PDF 三特异性ADC平台相较于双特异性ADC提供潜在的治疗优势 Tri-specific ADC platform offers potential therapeutic advantage over bi-specific ADC Yang Wang, Lixia Cao, Cui Feng, Fangdun Jiang, lixia Gu, Chen Li, Yifan Yang, Qi Zhang, Ming Zhou, Cancan Li, Wei Huang, Bonan Yan, Ziping Wei, Yuhong Zhou
• 6940 · PDF 一种同类首创的PD-L1/B7-H3/VEGF三特异性ADC通过直接细胞毒性、免疫检查点阻断和VEGF抑制实现增强的临床前抗肿瘤疗效 A first-in-class PD-L1/B7-H3/VEGF tri-specific ADC achieves enhanced preclinical antitumor efficacy through direct cytotoxicity, immune checkpoint blockade and VEGF inhibition Jiajia Pan, Pengfei Wang, Hongwang He, Mengfan Peng, Meng Cheng, Jie Zhang, Chengyi Ju, Jun Wang, Li Li, Hui Feng
• 6941 · PDF 靶向MUC1*两种不同生长因子受体形式与HER2或alpha-v-beta-6的双特异性和三特异性ADC抑制肿瘤复发并克服获得性耐药 Bi- and tri-specific ADCs that target two distinct growth factor receptor forms of MUC1* and HER2 or alpha-v-beta-6 inhibit tumor recurrence and overcome acquired resistance Cynthia Carol Bamdad, Benoit J. Smagghe, Scott Moe, Mark G. Carter, Kevin R. Yi, Michael J. Nash, Robert McDermott, Trevor J. Grant, Salvatore Marchese, Daniel S. Miller, Natalie K. Miller, Andrew K. Stewart
• 6942 · PDF 用于ADC MATCH试验的HER2、TROP2和NECTIN4 IHC预测算法的验证 Validation of HER2, TROP2, and NECTIN4 IHC prediction algorithms for the ADC MATCH trial Kyle A. Beauchamp, Elizabeth Mauer, Kaveri Nadhamuni, Elizabeth morency, Alia Zander, Xingyu Zheng, Katherine Mclean, Sayantoni Mukhopadhyay, Seung Won Hyun, Chithra Sangli, Kate Sasser, Halla Nimeiri, Charles Koyias, Michelle Ting-Lin, Funda Meric-Bernstam
• 6943 · PDF 用于转移性去势抵抗性前列腺癌的具有双载荷ADC的双特异性抗体 Bispecific antibody with dual-payload ADC for metastatic castration-resistant prostate cancer Wenkai Zhao, Xiaofei Zhou, Ting Wang, Furong Guo, Huijie Zhao, Ning Wang, Teddy Yang, Ying Lei, Li Tong, Fei Peng
• 6944 · PDF 一种新型且高度差异化的、具有低眼毒性风险的FGFR2b靶向ADC的临床前评价 Preclinical evaluation of a novel and highly differentiated FGFR2b-targeting ADC with low risk of ocular toxicity Zhaojun An, Jia Ge, Zhiqiang Xu, Yuhao Wang, Barry Duplantis, Quan Yu, Xiangyu He, Yi Li
• 6945 · PDF HDM2024：一种新型EGFR和HER3双特异性抗体-药物偶联物，展现出卓越的抗肿瘤活性和良好的毒理学特征 HDM2024: A novel EGFR and HER3 bispecific antibody-drug conjugate exhibits superior antitumor activity and favorable toxicological profile Qingyu Shu, Yan Xia, Zhaofeng Qin, Shengxing Zhao, Yang Chen, Rongrong He, Hao Pan, Hongwen Li, Dongzhou Jeffrey Liu
• 6946 · PDF BCG017的临床前评价：一种靶向PTK7和EGFR的新型双特异性ADC Preclinical evaluation of BCG017, a novel bispecific ADC targeting PTK7 and EGFR Zipeng Zeng, Na Zhang, Chengzhang Shang, Yi Yang
• 6947 · PDF 一种靶向5T4和MUC1的新型双特异性抗体-药物偶联物BCG016展现出强劲的临床前抗肿瘤活性 A novel bispecific antibody-drug conjugate, BCG016, that targets 5T4 and MUC1, demonstrates robust preclinical antitumor activity Zipeng Zeng, Yangyang Xu, Chengzhang Shang, Yi Yang
• 6948 · PDF 一种靶向CEACAM5和CDH17的新型双特异性抗体-药物偶联物展现出强效抗肿瘤活性和增强的肿瘤选择性 A novel bispecific antibody-drug conjugate targeting CEACAM5 and CDH17 exhibits potent anti-tumor activity and enhanced tumor-selectivity Jinxiu Hou, Tingting Gu, Lisha Dong, Jiyuan Tian, Xiaoqian Chen, Dandan Liu, Yongxin Shang, Rongmei Yan, Kezhen Ye, Liang Tian, Jian Peng, Zhenping Zhu
• 6949 · PDF 一种新型多模态PD-L1-ADC有望成为泛实体瘤治疗中具有增强肿瘤特异性的潜在BIC候选药物 A novel multi-modal PD-L1-ADC could be a potential BIC candidate treatment for pan-solid tumors with enhanced tumor-specificity Tao Yang, Hang Ke, Feiyu Peng, Jialin Li, Cen Chen, Lei Zhang, Faming Zhang, Henry Li

在会议检索中浏览本分会场